AR007493A1 - Microparticulas secadas por rociado como vehiculos terapeuticos para uso en terapia genetica - Google Patents

Microparticulas secadas por rociado como vehiculos terapeuticos para uso en terapia genetica

Info

Publication number
AR007493A1
AR007493A1 ARP970101333A ARP970101333A AR007493A1 AR 007493 A1 AR007493 A1 AR 007493A1 AR P970101333 A ARP970101333 A AR P970101333A AR P970101333 A ARP970101333 A AR P970101333A AR 007493 A1 AR007493 A1 AR 007493A1
Authority
AR
Argentina
Prior art keywords
spray dried
genetic therapy
dried microparticles
therapeutic vehicles
microparticles
Prior art date
Application number
ARP970101333A
Other languages
English (en)
Original Assignee
Andaris Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Andaris Ltd filed Critical Andaris Ltd
Publication of AR007493A1 publication Critical patent/AR007493A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1277—Processes for preparing; Proliposomes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Micropartículas, que son lisas y esféricas y por lo menos 90% de las cuales tiene un tamano de partícula medio de masa de 1 a 20 µm, comprenden una mezclasustancialmente uniforme de un agente para terapia genética y un excipiente. Por ejemplo, sepuede administrar de esa manera un gen expuesto o encapsulado,empleando, un inhalador de polvo seco.
ARP970101333A 1996-04-03 1997-04-03 Microparticulas secadas por rociado como vehiculos terapeuticos para uso en terapia genetica AR007493A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9607035.4A GB9607035D0 (en) 1996-04-03 1996-04-03 Spray-dried microparticles as therapeutic vehicles
GB9601379 1996-06-07

Publications (1)

Publication Number Publication Date
AR007493A1 true AR007493A1 (es) 1999-11-10

Family

ID=26308516

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP970101333A AR007493A1 (es) 1996-04-03 1997-04-03 Microparticulas secadas por rociado como vehiculos terapeuticos para uso en terapia genetica

Country Status (14)

Country Link
EP (1) EP0936902B1 (es)
JP (1) JP2000507568A (es)
AR (1) AR007493A1 (es)
AT (1) ATE243027T1 (es)
AU (1) AU715512B2 (es)
CA (1) CA2250478A1 (es)
DE (1) DE69722952T2 (es)
DK (1) DK0936902T3 (es)
ES (1) ES2201283T3 (es)
GB (1) GB9607035D0 (es)
NO (1) NO984462L (es)
PT (1) PT936902E (es)
WO (1) WO1997036578A1 (es)
ZA (1) ZA972837B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6270795B1 (en) 1995-11-09 2001-08-07 Microbiological Research Authority Method of making microencapsulated DNA for vaccination and gene therapy
ATE192334T1 (de) 1995-11-09 2000-05-15 Microbiological Res Authority Mikroverkapselte dna zur impfung und gentherapie
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
GB9810236D0 (en) 1998-05-13 1998-07-08 Microbiological Res Authority Improvements relating to encapsulation of bioactive agents
US6406719B1 (en) 1998-05-13 2002-06-18 Microbiological Research Authority Encapsulation of bioactive agents
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
US20030188679A1 (en) * 2000-08-25 2003-10-09 Eugen Schwarz Powdered mannitol and mannitol-containing compositions
MXPA04005865A (es) 2001-12-19 2004-09-13 Nektar Therapeutics Suministro de aminoglucosidos a los pulmones.
US9339459B2 (en) 2003-04-24 2016-05-17 Nektar Therapeutics Particulate materials
CA2566199C (en) 2004-05-12 2013-10-22 Baxter International Inc. Delivery of as-oligonucleotide microspheres to induce dendritic cell tolerance for the treatment of autoimmune type 1 diabetes
WO2005112894A1 (en) 2004-05-12 2005-12-01 Baxter International Inc. Nucleic acid microspheres, production and delivery thereof
EP1834651A1 (en) * 2006-03-15 2007-09-19 Universiteit Gent Compositions and methods for veterinary vaccination
EP2056883B1 (en) 2006-08-04 2021-09-22 Baxter International Inc. Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes
JP5744513B2 (ja) 2007-04-17 2015-07-08 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ 肺送達のための核酸微小粒子
DE102009033196A1 (de) * 2009-07-14 2011-01-20 Beiersdorf Ag Kosmetische Zubereitung mit einem Gehalt an dispergierten Mikrosphären
KR20210056331A (ko) * 2018-07-23 2021-05-18 트랜슬레이트 바이오 인코포레이티드 전령 rna의 건조 분말 제형
US20220096375A1 (en) * 2019-01-09 2022-03-31 Ziccum Ab Stabilized non-enveloped virus compositions

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9107628D0 (en) * 1991-04-10 1991-05-29 Moonbrook Limited Preparation of diagnostic agents
EP0606486B1 (en) * 1992-06-12 2001-08-29 Teijin Limited Pharmaceutical preparation for intra-airway administration
ATE222754T1 (de) * 1992-06-12 2002-09-15 Teijin Ltd Ultrafeines pulver zur inhalation und dessen herstellung
JPH08511418A (ja) * 1993-04-19 1996-12-03 メディソーブ・テクノロジーズ・インターナショナル・リミテッド・パートナーシップ 生分解性極微粒子からのアンチセンスオリゴデオキシリボヌクレオチドの徐放運搬による長期作用のある処置
ES2245780T3 (es) * 1994-05-18 2006-01-16 Nektar Therapeutics Metodos y composiciones para la formulacion de interferones como un polvo seco.
CZ92497A3 (en) * 1994-09-29 1997-08-13 Andaris Ltd Micro-particles of water soluble material intended for use in therapy or diagnosis, inhaling apparatus containing such particles and application of a therapeutical agent
WO1996027393A1 (en) * 1995-03-07 1996-09-12 University Of Pittsburgh A dry powder formulation for gene therapy
WO1997003702A1 (en) * 1995-07-21 1997-02-06 Brown University Research Foundation A method for gene therapy using nucleic acid loaded polymeric microparticles

Also Published As

Publication number Publication date
ES2201283T3 (es) 2004-03-16
CA2250478A1 (en) 1997-10-09
GB9607035D0 (en) 1996-06-05
JP2000507568A (ja) 2000-06-20
ATE243027T1 (de) 2003-07-15
DK0936902T3 (da) 2003-10-06
NO984462D0 (no) 1998-09-25
ZA972837B (en) 1998-04-03
NO984462L (no) 1998-09-25
DE69722952D1 (de) 2003-07-24
PT936902E (pt) 2003-11-28
WO1997036578A1 (en) 1997-10-09
EP0936902A1 (en) 1999-08-25
EP0936902B1 (en) 2003-06-18
AU715512B2 (en) 2000-02-03
AU2302097A (en) 1997-10-22
DE69722952T2 (de) 2003-12-11

Similar Documents

Publication Publication Date Title
AR007493A1 (es) Microparticulas secadas por rociado como vehiculos terapeuticos para uso en terapia genetica
MX9702357A (es) Microparticulas secadas por aspersion como vehiculos terapeuticos.
TR200100144T2 (tr) Farmasötik aerosol formülasyonu
HUP0003990A3 (en) Methods of treating capsules and dry, powdered pharmaceutical formulations
PT904056E (pt) Processo e dispositivo para inalacao de medicamentos particulados
GB2231495A (en) Enhanced uptake drug delivery system
BR9812693A (pt) Uso de um agente bioativo, processo para formar uma microestrutura perfurada, microestrutura perfurada, processo para aumentar a dispersibilidade de um pó, pó de microestrutura perfurada, pó tendo dispersibilidade aumentada, sistema de inalação para a administração pulmonar de um agente bioativo a um paciente, e, processo para a liberação pulmonar de um ou mais agentes bioativos
EE9700176A (et) Kuivpulbriinhalaatorites kasutatav pulber, selle valmistamismeetod, selles kasutatavad osakesed ja meetod nende valmistamiseks ning pulbri lisandi kasutamine
BR9006924A (pt) Formulacao para tratamento de sintomas e doencas,uso de formulacao para o tratamento de sintomas e doencas,metodo para o tratamento de sintomas e doencas,distribuicao de agentes medicinais e terapeuticos para o tratamento de sintomas e doencas e combinacao para administracao em mamiferos
DE69533744D1 (de) Yttria partikelförmiges gut
BR0012351A (pt) Pós consistindo de partìculas com uma superfìcie perfeitamente macia, para uso como veìculos para a preparação de misturas de inalação com medicamentos micronizados e o método para sua preparação
BR9510210A (pt) Dispositivo de inalação e processo para dispersão de uma substância farmaceuticamente ativa em uma câmara de dispersão e para administração de uma dose de uma substância farmaceuticamente ativa em pó
HUT76258A (en) Compositions comprising dna damaging agents and p53, and methods for uses thereof
BR9912653A (pt) Vìrus de herpes atenuado, cepa de vìrus, célula dendrìtica, processo para produzir um célula, composição farmacêutica, uso de um vìrus, e, processo para executar a terapia de gene em um paciente humano ou animal ou para tratar ou prevenir uma infecção patogênica ou câncer para tratar paciente animal
DE69840495D1 (de) Darreichungsform, welche rasche dispersionseigenschaften entfaltet, anwendungsverfahren sowie verfahren zur herstellung derselben
NO934315D0 (no) Farmas!ytisk b{rer
HUP0001170A3 (en) Pharmaceutical compositions containing benzimidazole-2-carbamate derivatives as active ingredients for the treatment of viral infections and cancer
AR002944A1 (es) Uso de una composicion de gel acuosa que contiene una o mas drogas que son eficaces para tratar hemorroides para la preparacion de un medicamento y dicha composicion de gel acuosa
ATE268605T1 (de) Pharmazeutische akzeptabel dnase zusammensetzung
PT1010688E (pt) 2-fenil-1-(3,4-di-hidroxi-5-nitrofenil)-1-etanonas substituidas seu uso no tratamento de algumas perturbacoes do sistema nervoso central e periferico e formulacoes do sistema nervoso central e periferico e formulacoes farmaceuticas que as contem
DK1107737T3 (da) Mikropartikler til anvendelse ved nålelös injektion
BR9809284A (pt) Construto e processo para expressão de polinucleotìdeo em altos nìveis
ATE233534T1 (de) Mittel zur behandlung keratinischer fasern
IL121272A (en) Pharmaceutical compositions comprising adenosine and their use for treating or preventing leukopenia
ES2182983T3 (es) Formulaciones para la liberacion de peptidos.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal